Rational Design of Selective IL-2-based Activators for CAR T Cells Using AlphaFold3 and Physics-Informed Machine Learning

Abstract Recombinant human Interleukin-2 (rhIL-2, Aldesleukin) is used in immunotherapy for metastatic melanoma and renal cell carcinoma. Low-dose IL-2 has been investigated for administration after adoptive T cell transfer to enhance CAR T expansion and sustain effector function. However, systemic IL-2 can cause severe toxicities and promote expansion of regulatory T cells (Tregs). Previous attempts at mitigating cytokine-mediated side effects involved isolating CAR T cell signaling from endogenous immune responses by developing IL-2/IL-2Rβ based selective ligand–receptors systems. Expressing these variant orthogonal (ortho)IL2-Rβ receptors in CAR T cells and supplying variant orthoIL-2, was shown to dramatically improve selectivity in CAR T cell expansion and anti-tumoral potency in a leukemia mouse model. This study describes the computational design of synthetic orthogonal cytokine receptor-ligand systems based on the scaffolds of the human canonical IL-2 and IL-2Rβ. Leveraging state-of-the-art AlphaFold3 (AF3) structure prediction capabilities and a physics-informed constrained sequence generator (CSG), the pipeline generates, filters and ranks sets of putative orthoIL-2/orthoIL-2Rβ mutant designs. Variants displaying minimal predicted off-target interactions and enhanced in target contacts are prioritized for structural modelling. Top designs showed outstanding AF3 structural and interfacial quality metrics ipTM and pTM, with averages between cognate pairs of 0.724±0.05 and 0.770±0.042, respectively. All in-silico hits showed ipTM